Literature DB >> 18766086

Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat.

Alexander M Mathes1, Darius Kubulus, Lina Waibel, Julia Weiler, Paul Heymann, Beate Wolf, Hauke Rensing.   

Abstract

OBJECTIVE: Melatonin may attenuate organ damage via direct antioxidative properties, and was recently demonstrated to reduce cardiac and hepatic injury through receptor-dependent effects. However, the relevance of an isolated activation of melatonin receptors for organ protection, excluding direct antioxidant effects, has not been established yet. This study was designed to investigate whether therapy with melatonin receptor agonist and hypnotic substance ramelteon may improve liver function, hepatic perfusion, and hepatic integrity after hemorrhagic shock in rat.
DESIGN: Prospective, randomized, controlled study.
SETTING: University research laboratory.
SUBJECTS: Male Sprague-Dawley rats (n = 10 per group).
INTERVENTIONS: Animals underwent hemorrhagic shock (mean arterial pressure 35 +/- 5 mm Hg for 90 mins) and were resuscitated with shed blood and Ringer's lactate (2 hrs). At the end of shock, animals were treated with ramelteon (1.0 mg/kg intravenously), melatonin receptor antagonist luzindole plus ramelteon (each 1.0 mg/kg intravenously), or vehicle.
MEASUREMENTS AND MAIN RESULTS: In vitro, ramelteon displayed no relevant antioxidant capacity in an 2,2'-Azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) assay, compared with melatonin. In vivo, liver function was assessed by plasma disappearance rate of indocyanine green, and intravital microscopy was performed for evaluation of hepatic perfusion index, nicotinamide adenine dinucleotide phosphate autofluorescence, and hepatic integrity. Compared with vehicle controls, ramelteon therapy significantly improved plasma disappearance rate of indocyanine green (7.89 +/- 2.12% vs. 13.67 +/- 2.51%; p = 0.006), hepatic perfusion index (352.04 +/- 111.78 pl/sec/mm vs. 848.81 +/- 181.38 pl/sec/mm; p = 0.002), nicotinamide adenine dinucleotide phosphate autofluorescence and hepatocellular injury. Coadministration of luzindole abolished the protective effect of ramelteon with respect to liver function and nicotinamide adenine dinucleotide phosphate autofluorescence.
CONCLUSIONS: Ramelteon therapy improves liver function, hepatic perfusion, and hepatocellular integrity after hemorrhagic shock in rat. This demonstrates that an isolated activation of melatonin receptors may be sufficient for organ protection, independent from direct antioxidant effects. The hypnotic ramelteon could thus play an interesting role in future sedation concepts for critical care patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766086     DOI: 10.1097/CCM.0b013e318187b863

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

Review 1.  Hepatoprotective actions of melatonin: possible mediation by melatonin receptors.

Authors:  Alexander M Mathes
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

2.  Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms.

Authors:  Senthil Kumaran Satyanarayanan; Yin-Hwa Shih; Yu-Chuan Chien; Shih-Yi Huang; Piotr Gałecki; Siegfried Kasper; Jane Pei-Chen Chang; Kuan-Pin Su
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

3.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

4.  Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms.

Authors:  Nobutaka Shimizu; Masahiro Nozawa; Koichi Sugimoto; Yutaka Yamamoto; Takafumi Minami; Taiji Hayashi; Kazuhiro Yoshimura; Tokumi Ishii; Hirotsugu Uemura
Journal:  Res Rep Urol       Date:  2013-05-08

5.  Melatonin Receptor Agonists as the "Perioceutics" Agents for Periodontal Disease through Modulation of Porphyromonas gingivalis Virulence and Inflammatory Response.

Authors:  Wei Zhou; Xuan Zhang; Cai-Lian Zhu; Zhi-Yan He; Jing-Ping Liang; Zhong-Chen Song
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

6.  Ramelteon protects against human pulmonary microvascular endothelial cell injury induced by lipopolysaccharide (LPS) via activating nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway.

Authors:  Wenjun Yang; Yang Zhang; Dahao Lu; Tianfeng Huang; Keshi Yan; Weiwei Wang; Ju Gao
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

7.  Resveratrol therapy improves liver function via estrogen-receptors after hemorrhagic shock in rats.

Authors:  Alexander Wolf; Tobias Fink; Jochen Hinkelbein; Thilo Mertke; Thomas Volk; Alexander Mathes
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

8.  Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice.

Authors:  G O'Neal-Moffitt; V Delic; P C Bradshaw; J Olcese
Journal:  Mol Neurodegener       Date:  2015-07-11       Impact factor: 14.195

9.  Endogenous and Exogenous Melatonin Exposure Attenuates Hepatic MT1 Melatonin Receptor Protein Expression in Rat.

Authors:  Alexander M Mathes; Paul Heymann; Christian Ruf; Ragnar Huhn; Jochen Hinkelbein; Thomas Volk; Tobias Fink
Journal:  Antioxidants (Basel)       Date:  2019-09-18

10.  Melatonin receptor agonist protects against acute lung injury induced by ventilator through up-regulation of IL-10 production.

Authors:  Geng-Chin Wu; Chung-Kan Peng; Wen-I Liao; Hsin-Ping Pao; Kun-Lun Huang; Shi-Jye Chu
Journal:  Respir Res       Date:  2020-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.